Healthcare provider profile · identity verified

Inga Tuluca, MD

Internal Medicine · STAMFORD, CT · NPI 1619924057

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	437	126
Atorvastatin Calcium	Atorvastatin Calcium	395	121
Levothyroxine Sodium	Levothyroxine Sodium	394	96
Losartan Potassium	Losartan Potassium	290	74
Amlodipine Besylate	Amlodipine Besylate	289	80
Escitalopram Oxalate	Escitalopram Oxalate	196	45
Alprazolam	Alprazolam	166	51
Pantoprazole Sodium	Pantoprazole Sodium	165	51
Zolpidem Tartrate	Zolpidem Tartrate	154	38
Metoprolol Succinate	Metoprolol Succinate	151	43
Sertraline Hcl	Sertraline Hcl	150	37
Olmesartan Medoxomil	Olmesartan Medoxomil	130	36
Metformin Hcl	Metformin Hcl	122	35
Pravastatin Sodium	Pravastatin Sodium	117	33
Omeprazole	Omeprazole	115	38
Lisinopril	Lisinopril	106	33
Meloxicam	Meloxicam	106	51
Clonazepam	Clonazepam	100	20
Eliquis	Apixaban	99	24
Lorazepam	Lorazepam	95	19
Ezetimibe	Ezetimibe	93	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	93	25
Furosemide	Furosemide	90	25
Simvastatin	Simvastatin	89	25
Gabapentin	Gabapentin	85	24
Fluticasone Propionate	Fluticasone Propionate	83	55
Allopurinol	Allopurinol	81	19
Ozempic	Semaglutide	79	14
Tamsulosin Hcl	Tamsulosin Hcl	78	24
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	76	21
Mirtazapine	Mirtazapine	72	11
Famotidine	Famotidine	70	25
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	65	19
Duloxetine Hcl	Duloxetine Hcl	62	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	60	52
Citalopram Hbr	Citalopram Hydrobromide	60	15
Methylprednisolone	Methylprednisolone	60	54
Metoprolol Tartrate	Metoprolol Tartrate	59	16
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	59	18
Trazodone Hcl	Trazodone Hcl	59	14
Quetiapine Fumarate	Quetiapine Fumarate	57	11
Eszopiclone	Eszopiclone	52	17
Spironolactone	Spironolactone	52	15
Synthroid	Levothyroxine Sodium	52	17
Alendronate Sodium	Alendronate Sodium	48	11
Hydrochlorothiazide	Hydrochlorothiazide	48	14
Tradjenta	Linagliptin	48	suppressed
Valacyclovir	Valacyclovir Hcl	48	19
Donepezil Hcl	Donepezil Hcl	47	suppressed
Myrbetriq	Mirabegron	47	15
Valsartan	Valsartan	47	14
Clopidogrel	Clopidogrel Bisulfate	46	13
Januvia	Sitagliptin Phosphate	41	suppressed
Prednisone	Prednisone	41	16
Nebivolol Hcl	Nebivolol Hcl	40	13
Clonidine Hcl	Clonidine Hcl	37	suppressed
Montelukast Sodium	Montelukast Sodium	37	11
Azithromycin	Azithromycin	36	35
Nitrofurantoin	Nitrofurantoin Macrocrystal	35	28
Potassium Chloride	Potassium Chloride	35	suppressed
Xarelto	Rivaroxaban	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	30	suppressed
Finasteride	Finasteride	29	suppressed
Irbesartan	Irbesartan	29	suppressed
Lovastatin	Lovastatin	29	suppressed
Atenolol	Atenolol	28	suppressed
Torsemide	Torsemide	28	suppressed
Bupropion Xl	Bupropion Hcl	27	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	27	25
Metformin Hcl Er	Metformin Hcl	27	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Ramipril	Ramipril	27	suppressed
Gemtesa	Vibegron	26	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	26	suppressed
Temazepam	Temazepam	25	suppressed
Clobetasol Propionate	Clobetasol Propionate	24	17
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Jardiance	Empagliflozin	23	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	23	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	23	suppressed
Carvedilol	Carvedilol	22	suppressed
Meclizine Hcl	Meclizine Hcl	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	19
Dexlansoprazole Dr	Dexlansoprazole	21	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	20	14
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	20	suppressed
Celecoxib	Celecoxib	17	suppressed
Estradiol	Estradiol	17	suppressed
Telmisartan	Telmisartan	16	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Livalo	Pitavastatin Calcium	15	suppressed
Prolia	Denosumab	15	suppressed
Risperidone	Risperidone	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Diazepam	Diazepam	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Budesonide Dr	Budesonide	13	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Tramadol Hcl	Tramadol Hcl	13	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error